[시장보고서]땅콩 알레르기 치료 시장 : 규모, 점유율, 동향 분석, 약품 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

땅콩 알레르기 치료 시장 : 규모, 점유율, 동향 분석, 약품 클래스별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2033년)

Peanut Allergy Treatment Market Size, Share & Trends Analysis Report By Drug Class (Antihistamines, Epinephrine, Immunotherapies), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033

상품코드 : 1771629

리서치사 : Grand View Research

발행일 : 2025년 06월

페이지 정보 : 영문 150 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,861,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,350,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,329,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

땅콩 알레르기 치료 시장의 성장과 동향 :

Grand View Research의 최신 보고서에 따르면 세계 땅콩 알레르기 치료 시장 규모는 2033년까지 14억 6,150만 달러에 이를 것으로 예측됩니다.

이 시장은 2025년부터 2033년까지 연평균 복합 성장률(CAGR) 11.43%로 성장할 것으로 예측됩니다.

주요 시장 진출 기업은 다양한 전략을 통해 땅콩 알레르기 치료의 파이프라인을 강화하고 있습니다. Brandon Capital로부터 2,000만 달러의 투자를 획득했습니다. 이 자금 조달에 의해 Aravax는 땅콩에 알레르기 반응을 일으키는 사람을 대상으로 한 PVX108의 제II상 임상시험을 개시할 수 있게 되었습니다.

땅콩 알레르기 치료제의 승인 수가 증가하고 있다는 점도 시장을 자극하고 있습니다. 2020년 1월, 미국 식품의약국(FDA)은 Aimmune Therapeutics, Inc.가 개발한 PALFORZIA [땅콩(Arachis hypogaea) 알레르겐 분말-dnfp]에 대한 판매를 승인했습니다. PALFORZIA는 땅콩 알레르기가 있는 개인을 위해 승인된 최초의 면역 치료제입니다. 실수로 땅콩을 섭취했을 때 유발되는 아나필락시스를 포함한 알레르기 반응을 줄이기 위해 고안된 경구 면역 요법입니다.

2023년 1분기 현재 몇 가지 유망한 파이프라인 제품이 임상 개발 중입니다. 이들에는 DBV 테크놀로지스(DBV Technologies)의 비아스킨 피넛(Viaskin Peanut), 두픽시엔트(Dupixent)의 CA002, 그리고 사노피(Sanofi)와 리제네론(Regeneron)의 협력 노력으로 개발된 카말레그(Camallegr)가 포함됩니다. 또한 ADP101, VE416, INP20, CNP-201 등의 자산도 개발 중입니다.

땅콩 알레르기 치료 시장 보고서 하이라이트

에피네프린 부문이 2024년의 주요 시장 점유율을 차지했습니다.
투여 경로별로는 주사제가 2024년 시장을 석권했습니다.
유통 채널별로는 병원 약국 부문이 2024년에 최대 시장 점유율을 차지했습니다.
북미는 이 시장에서 확고한 지위를 확립하고 있습니다. 이것은 유전자 치료, 생물제제, 기타 면역조절 개입 등 땅콩 알레르기의 근본적인 원인에 대처하기 위한 새로운 치료 전략을 현재 연구하고 있는 수많은 제약회사, 학술기관, 연구기관이 존재하기 때문입니다.

지역별 시장 점유율 분석, 2024년 및 2033년
지역 시장 대시보드
시장 규모와 예측 동향 분석, 2021-2033년
북미
- 국가별, 2021년-2033년
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카
- 사우디아라비아
- 아랍에미리트(UAE)
- 쿠웨이트

제8장 경쟁 구도

참가자 개요
기업의 시장 포지셔닝 분석
기업 분류
전략 매핑
기업 프로파일/상장 기업
- Aimmune Therapeutics(Nestle Health Science)
- DBV Technologies
- Sanofi
- ALK-Abello
- Prota Therapeutics
- Camallergy
- Aravax
- Arch Pharmalabs
- Genentech

SHW

영문 목차

영문목차

Peanut Allergy Treatment Market Growth & Trends:

The global peanut allergy treatment market size is expected to reach USD 1,461.5 million by 2033, according to a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 11.43% from 2025 to 2033. Some of the key factors propelling the market growth include a robust product pipeline, high disease prevalence, advancement in the drug delivery system, and strategic initiatives by key players.

Key market players are bolstering their pipeline for peanut allergy treatment through various strategies. For instance, Aravax initiated its series B funding round in December 2022, securing a USD 20 million investment from renowned Australian healthcare entrepreneurs Tenmile and Brandon Capital. This financing will enable Aravax to commence phase II clinical trials of PVX108, targeting individuals who experience allergic reactions to peanuts. Such fundings are expected to drive advancements in research and development programs.

The market is stimulated by the increasing number of product approvals for peanut allergy treatment. In January 2020, the U.S. Food and Drug Administration (FDA) granted authorization to PALFORZIA [Peanut (Arachis hypogaea) Allergen Powder-dnfp], developed by Aimmune Therapeutics, Inc. PALFORZIA is the first immunotherapy medication approved for individuals with peanut allergies. It is an oral immune therapy designed to reduce allergy responses, including anaphylaxis triggered by accidental peanut ingestion. It is intended for individuals who have a confirmed allergy, with initial dose escalation recommended for children aged four to 17.

As of the first quarter of 2023, several promising pipeline products are undergoing clinical development. These include Viaskin Peanut by DBV Technologies, CA002 by Dupixient, and Camallegr, a collaborative effort between Sanofi and Regeneron. Additionally, other assets such as ADP101, VE416, INP20, and CNP-201 are also in development. The introduction of these medications is anticipated to contribute to the growth and expansion of the market during the projected forecast period.

Peanut Allergy Treatment Market Report Highlights:

The epinephrine segment held the major market share in 2024. The standard of care for anaphylaxis treatment has been epinephrine auto-injectors, which are also essential in the management of allergies in emergency situations.
By route of administration, the injectable segment dominated the market in 2024 owing to the development of injectable treatments that are practical, less painful, and easier to use for patients is being pursued in response to the growing emphasis on patient-centered care. This includes looking at alternative delivery systems for injectable therapies, such as wearable technology or auto-injectors.
By distribution channel, the hospital pharmacy segment held the largest market share in 2024. Hospital pharmacies put more of an emphasis on offering patient support and information for people with peanut allergies.
North America has established a strong regional position in the market. This is due to the presence of numerous pharmaceutical companies, academic institutions, and research organizations currently looking into new therapeutic strategies to address the underlying causes of peanut allergies, including gene therapy, biologics, and other immunomodulatory interventions.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Drug Class
- 1.2.2. Route of Administration
- 1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Peanut Allergy Treatment Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Patent Expiry Analysis
- 3.3.5. Pricing Analysis

Chapter 4. Peanut Allergy Treatment Market: Drug Class Business Analysis

4.1. Drug Class Market Share, 2024 & 2033
4.2. Drug Class Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
4.4. Antihistamines
- 4.4.1. Antihistamines Market, 2021 - 2033 (USD Million)
4.5. Epinephrine
- 4.5.1. Epinephrine Market, 2021 - 2033 (USD Million)
4.6. Immunotherapies
- 4.6.1. Immunotherapies Market, 2021 - 2033 (USD Million)
4.7. Others
- 4.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Peanut Allergy Treatment Market: Route of Administration Business Analysis

5.1. Route of Administration Market Share, 2024 & 2033
5.2. Route of Administration Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
5.4. Oral
- 5.4.1. Oral Market, 2021 - 2033 (USD Million)
5.5. Injectable
- 5.5.1. Injectable Market, 2021 - 2033 (USD Million)
5.6. Others
- 5.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Peanut Allergy Treatment Market: Distribution Channel Business Analysis

6.1. Distribution Channel Market Share, 2024 & 2033
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
6.4. Hospital Pharmacies
- 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Million)
6.5. Retail Pharmacies
- 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
6.6. Others
- 6.6.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Peanut Allergy Treatment Market: Regional Estimates & Trend Analysis

7.1. Regional Market Share Analysis, 2024 & 2033
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
7.4. North America
- 7.4.1. North America Peanut Allergy Treatment Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
- 7.4.2. U.S.
  - 7.4.2.1. Key Country Dynamics
  - 7.4.2.2. Target Disease Prevalence
  - 7.4.2.3. Regulatory Framework
  - 7.4.2.4. Reimbursement Framework
  - 7.4.2.5. U.S. Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.3. Canada
  - 7.4.3.1. Key Country Dynamics
  - 7.4.3.2. Target Disease Prevalence
  - 7.4.3.3. Regulatory Framework
  - 7.4.3.4. Reimbursement Framework
  - 7.4.3.5. U.S. Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.4.4. Mexico
  - 7.4.4.1. Key Country Dynamics
  - 7.4.4.2. Target Disease Prevalence
  - 7.4.4.3. Regulatory Framework
  - 7.4.4.4. Reimbursement Framework
  - 7.4.4.5. Mexico Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.5. Europe
- 7.5.1. Europe Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.2. UK
  - 7.5.2.1. Key Country Dynamics
  - 7.5.2.2. Target Disease Prevalence
  - 7.5.2.3. Regulatory Framework
  - 7.5.2.4. Reimbursement Framework
  - 7.5.2.5. Uk Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.3. Germany
  - 7.5.3.1. Key Country Dynamics
  - 7.5.3.2. Target Disease Prevalence
  - 7.5.3.3. Regulatory Framework
  - 7.5.3.4. Reimbursement Framework
  - 7.5.3.5. Germany Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.4. France
  - 7.5.4.1. Key Country Dynamics
  - 7.5.4.2. Target Disease Prevalence
  - 7.5.4.3. Regulatory Framework
  - 7.5.4.4. Reimbursement Framework
  - 7.5.4.5. France Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.5. Italy
  - 7.5.5.1. Key Country Dynamics
  - 7.5.5.2. Target Disease Prevalence
  - 7.5.5.3. Regulatory Framework
  - 7.5.5.4. Reimbursement Framework
  - 7.5.5.5. Italy Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.6. Spain
  - 7.5.6.1. Key Country Dynamics
  - 7.5.6.2. Target Disease Prevalence
  - 7.5.6.3. Regulatory Framework
  - 7.5.6.4. Reimbursement Framework
  - 7.5.6.5. Spain Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.7. Denmark
  - 7.5.7.1. Key Country Dynamics
  - 7.5.7.2. Target Disease Prevalence
  - 7.5.7.3. Regulatory Framework
  - 7.5.7.4. Reimbursement Framework
  - 7.5.7.5. Denmark Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.8. Sweden
  - 7.5.8.1. Key Country Dynamics
  - 7.5.8.2. Target Disease Prevalence
  - 7.5.8.3. Regulatory Framework
  - 7.5.8.4. Reimbursement Framework
  - 7.5.8.5. Sweden Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.5.9. Norway
  - 7.5.9.1. Key Country Dynamics
  - 7.5.9.2. Target Disease Prevalence
  - 7.5.9.3. Regulatory Framework
  - 7.5.9.4. Reimbursement Framework
  - 7.5.9.5. Norway Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.6. Asia Pacific
- 7.6.1. Asia Pacific Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.2. Japan
  - 7.6.2.1. Key Country Dynamics
  - 7.6.2.2. Target Disease Prevalence
  - 7.6.2.3. Regulatory Framework
  - 7.6.2.4. Reimbursement Framework
  - 7.6.2.5. Japan Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.3. China
  - 7.6.3.1. Key Country Dynamics
  - 7.6.3.2. Target Disease Prevalence
  - 7.6.3.3. Regulatory Framework
  - 7.6.3.4. Reimbursement Framework
  - 7.6.3.5. China Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.4. India
  - 7.6.4.1. Key Country Dynamics
  - 7.6.4.2. Target Disease Prevalence
  - 7.6.4.3. Regulatory Framework
  - 7.6.4.4. Reimbursement Framework
  - 7.6.4.5. India Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.5. Australia
  - 7.6.5.1. Key Country Dynamics
  - 7.6.5.2. Target Disease Prevalence
  - 7.6.5.3. Regulatory Framework
  - 7.6.5.4. Reimbursement Framework
  - 7.6.5.5. Australia Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.6. South Korea
  - 7.6.6.1. Key Country Dynamics
  - 7.6.6.2. Target Disease Prevalence
  - 7.6.6.3. Regulatory Framework
  - 7.6.6.4. Reimbursement Framework
  - 7.6.6.5. South Korea Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.6.7. Thailand
  - 7.6.7.1. Key Country Dynamics
  - 7.6.7.2. Target Disease Prevalence
  - 7.6.7.3. Regulatory Framework
  - 7.6.7.4. Reimbursement Framework
  - 7.6.7.5. Thailand Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.7. Latin America
- 7.7.1. Latin America Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.2. Brazil
  - 7.7.2.1. Key Country Dynamics
  - 7.7.2.2. Target Disease Prevalence
  - 7.7.2.3. Regulatory Framework
  - 7.7.2.4. Reimbursement Framework
  - 7.7.2.5. Japan Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.7.3. Argentina
  - 7.7.3.1. Key Country Dynamics
  - 7.7.3.2. Target Disease Prevalence
  - 7.7.3.3. Regulatory Framework
  - 7.7.3.4. Reimbursement Framework
  - 7.7.3.5. China Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
7.8. Middle East and Africa
- 7.8.1. Middle East and Africa Peanut Allergy Treatment Market Estimates and Forecasts, 2017 - 2030 (USD Million)
- 7.8.2. South Africa
  - 7.8.2.1. Key Country Dynamics
  - 7.8.2.2. Target Disease Prevalence
  - 7.8.2.3. Regulatory Framework
  - 7.8.2.4. Reimbursement Framework
  - 7.8.2.5. South Africa Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.3. Saudi Arabia
  - 7.8.3.1. Key Country Dynamics
  - 7.8.3.2. Target Disease Prevalence
  - 7.8.3.3. Regulatory Framework
  - 7.8.3.4. Reimbursement Framework
  - 7.8.3.5. Saudi Arabia Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.4. UAE
  - 7.8.4.1. Key Country Dynamics
  - 7.8.4.2. Target Disease Prevalence
  - 7.8.4.3. Regulatory Framework
  - 7.8.4.4. Reimbursement Framework
  - 7.8.4.5. UAE Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 7.8.5. Kuwait
  - 7.8.5.1. Key Country Dynamics
  - 7.8.5.2. Target Disease Prevalence
  - 7.8.5.3. Regulatory Framework
  - 7.8.5.4. Reimbursement Framework
  - 7.8.5.5. Kuwait Peanut Allergy Treatment Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

8.1. Participant Overview
8.2. Company Market Position Analysis
8.3. Company Categorization
8.4. Strategy Mapping
8.5. Company Profiles/Listing
- 8.5.1. Aimmune Therapeutics (Nestle Health Science)
  - 8.5.1.1. Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Product Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. DBV Technologies
  - 8.5.2.1. Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Product Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. Sanofi
  - 8.5.3.1. Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Product Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. ALK-Abello
  - 8.5.4.1. Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Product Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. Prota Therapeutics
  - 8.5.5.1. Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Product Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. Camallergy
  - 8.5.6.1. Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Product Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Aravax
  - 8.5.7.1. Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Product Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. Arch Pharmalabs
  - 8.5.8.1. Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Product Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. Genentech
  - 8.5.9.1. Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Product Benchmarking
  - 8.5.9.4. Strategic Initiatives

한글목차

땅콩 알레르기 치료 시장의 성장과 동향 :

땅콩 알레르기 치료 시장 보고서 하이라이트

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 땅콩 알레르기 치료 시장의 변수, 동향, 범위

제4장 땅콩 알레르기 치료 시장 : 약제 클래스의 비즈니스 분석

제5장 땅콩 알레르기 치료 시장 : 투여 경로의 비즈니스 분석

제6장 땅콩 알레르기 치료 시장 : 유통 채널의 비즈니스 분석

제7장 땅콩 알레르기 치료 시장 : 지역의 추정 및 예측 분석